Rheumatoid Arthritis

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) Trial

TEAR is a Phase IV investigator-initiated study. The study design is a multi-center, randomized, double-blind study (2X2 factorial design).The study start date was 5-17-04. The primary objective of the trial is to evaluate the relative efficacy of two clinically important decisions using the 28 joint count (DAS28) between 48 and 102 weeks after initiation of treatment:

  • To assess if it is better to intensively treat all early RA patients with multiple DMARDs or reserve this treatment only to those who do not appropriately respond to MTX monotherapy; And
     
  • To assess if the combination therapy of MTX plus etanercept is superior to the triple combination of MTX plus SSZ plus HCQ

Key personnel at the Clinic Coordinating Center (CCC) include:

Larry Moreland, MD Principal Investigator
Keslie Woodsd Program Manager
Sheree Carter, RN,MSN Study Administrator
Candice Griffin, MPH,MBA Quality Assurance Coordinator


Key personnel at the Statistical and Data Management Center (SDMC) include:

George Howard, DrPh Co-Principal Investigator
Stacey Cofield , PhD Assistant Director, SDMC
Tekeda Ferguson, MSPH, MPH Project Manager/Data Manager
Theresa McVie, MS Senior Statistician
Richard Mailhot, MS,MBA IT Manager
Doug Kennedy, MS Lead Programmer